0000899243-20-014540.txt : 20200529 0000899243-20-014540.hdr.sgml : 20200529 20200529160602 ACCESSION NUMBER: 0000899243-20-014540 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200527 FILED AS OF DATE: 20200529 DATE AS OF CHANGE: 20200529 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Shah Rajeev M. CENTRAL INDEX KEY: 0001619841 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38533 FILM NUMBER: 20927679 MAIL ADDRESS: STREET 1: 200 BERKELEY STREET STREET 2: 18TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Eidos Therapeutics, Inc. CENTRAL INDEX KEY: 0001731831 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 463733671 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 101 MONTGOMERY STREET, SUITE 2550 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: 650-391-9740 MAIL ADDRESS: STREET 1: 101 MONTGOMERY STREET, SUITE 2550 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-05-27 0 0001731831 Eidos Therapeutics, Inc. EIDX 0001619841 Shah Rajeev M. C/O RA CAPITAL MANAGEMENT, L.P. 200 BERKELY STREET, 18TH FLOOR BOSTON MA 02116 1 0 0 0 Stock Option (right to buy) 48.51 2020-05-27 4 A 0 21528 0.00 A 2030-05-27 Common Stock 21528 21528 D The shares subject to this option shall vest and become exercisable in a single installment on the earlier of (i) the first anniversary of the grant date, so that all of the underlying shares shall be vested on May 26, 2021, or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service with the Issuer through the vesting date. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2018 Stock Option and Incentive Plan, as amended). Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Manager"), the Reporting Person holds the option for the benefit of RA Capital Healthcare Fund, L.P. (the "Fund") and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Manager any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund and Account to the Manager. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock. /s/ Franco Valle, as Attorney-in-Fact 2020-05-29